Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN ...
We are enthusiastic to join forces with Madrigal Pharmaceuticals, drawing on their extensive knowledge together with our siRNA expertise to advance life changing therapies for people affected by liver ...
US biopharma Madrigal Pharmaceuticals, which is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has announced an exclusive global license ...
Ribo and Ribocure enter exclusive global licensing agreement with Madrigal for novel siRNA therapeutics targeting MASH: Suzhou, China Thursday, February 12, 2026, 15:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results